JP6189865B2 - 金属酵素阻害薬化合物 - Google Patents

金属酵素阻害薬化合物 Download PDF

Info

Publication number
JP6189865B2
JP6189865B2 JP2014553491A JP2014553491A JP6189865B2 JP 6189865 B2 JP6189865 B2 JP 6189865B2 JP 2014553491 A JP2014553491 A JP 2014553491A JP 2014553491 A JP2014553491 A JP 2014553491A JP 6189865 B2 JP6189865 B2 JP 6189865B2
Authority
JP
Japan
Prior art keywords
compound
disease
difluorophenyl
mmol
tetrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014553491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504095A (ja
JP2015504095A5 (enExample
Inventor
ジェイ． ホークストラ，ウイリアム
ジェイ． ホークストラ，ウイリアム
ジェイ． ショットジンガー，ロバート
ジェイ． ショットジンガー，ロバート
ダブリュー． ラファティー，ステファン
ダブリュー． ラファティー，ステファン
Original Assignee
ヴィアメット ファーマスーティカルズ，インコーポレイテッド
ヴィアメット ファーマスーティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィアメット ファーマスーティカルズ，インコーポレイテッド, ヴィアメット ファーマスーティカルズ，インコーポレイテッド filed Critical ヴィアメット ファーマスーティカルズ，インコーポレイテッド
Publication of JP2015504095A publication Critical patent/JP2015504095A/ja
Publication of JP2015504095A5 publication Critical patent/JP2015504095A5/ja
Application granted granted Critical
Publication of JP6189865B2 publication Critical patent/JP6189865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014553491A 2012-01-20 2013-01-18 金属酵素阻害薬化合物 Active JP6189865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589076P 2012-01-20 2012-01-20
US61/589,076 2012-01-20
PCT/US2013/022313 WO2013109998A1 (en) 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds

Publications (3)

Publication Number Publication Date
JP2015504095A JP2015504095A (ja) 2015-02-05
JP2015504095A5 JP2015504095A5 (enExample) 2016-03-03
JP6189865B2 true JP6189865B2 (ja) 2017-08-30

Family

ID=48799718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553491A Active JP6189865B2 (ja) 2012-01-20 2013-01-18 金属酵素阻害薬化合物

Country Status (14)

Country Link
US (3) US10221160B2 (enExample)
EP (1) EP2804858B1 (enExample)
JP (1) JP6189865B2 (enExample)
KR (1) KR102061137B1 (enExample)
CN (1) CN104136427B (enExample)
AU (2) AU2013209516A1 (enExample)
BR (1) BR112014017751B1 (enExample)
CA (1) CA2861339C (enExample)
DK (1) DK2804858T3 (enExample)
EA (1) EA026209B1 (enExample)
ES (1) ES2774267T3 (enExample)
IN (1) IN2014DN06792A (enExample)
PL (1) PL2804858T3 (enExample)
WO (1) WO2013109998A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140040235A (ko) 2011-06-19 2014-04-02 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
IN2014DN06792A (enExample) * 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
WO2015143154A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP2017507991A (ja) * 2014-03-19 2017-03-23 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942968C (en) * 2014-03-19 2022-03-15 William J. Hoekstra Antifungal compound process
JP6572234B2 (ja) * 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
AU2015231270B2 (en) * 2014-03-19 2019-03-07 Viamet Pharmaceuticals (NC), Inc. Antifungal compound process
CN109678791B (zh) 2014-03-19 2022-07-01 美国陶氏益农公司 1-(2,4-二氟苯)-2,2-二氟-2-(5-取代吡啶-2-基)乙酮及制备方法
US9914726B2 (en) 2014-03-19 2018-03-13 Vps-3, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ols and processes for their preparation
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP2017509646A (ja) * 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
CN107428724B (zh) 2015-03-19 2021-07-02 迈科维亚医药公司 抗真菌化合物及制备方法
BR112018005194B1 (pt) 2015-09-18 2022-11-08 Vps-3, Inc Processo para preparar um composto antifúngico
MX376201B (es) * 2015-12-30 2025-03-07 Nqp 1598 Ltd Compuestos inhibidores de metaloenzima.
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
CN109810049B (zh) * 2018-11-30 2021-01-15 深圳大学 一种含吡啶的化合物及其提取方法
WO2021143811A1 (zh) * 2020-01-17 2021-07-22 上海森辉医药有限公司 四氮唑类化合物的可药用盐及其结晶形式、制备方法和用途
AU2021361997A1 (en) * 2020-10-16 2023-06-15 Miralogx Llc Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders
WO2026006142A1 (en) * 2024-06-24 2026-01-02 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Azole compounds useful as inhibitors of voltage-dependent anion channel oligomerization

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8304282D0 (en) * 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
GB8305377D0 (en) 1983-02-25 1983-03-30 Pfizer Ltd Antifungal agents
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
AU4327585A (en) 1984-06-21 1986-01-02 Imperial Chemical Industries Plc Antifungal azole compounds
GB8415889D0 (en) 1984-06-21 1984-07-25 Ici Plc Antifungal azole compounds
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
GB9121456D0 (en) * 1991-10-10 1991-11-27 Pfizer Ltd Triazole antifungal agents
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5358939A (en) 1992-06-25 1994-10-25 Rohm And Haas Company Fungicidal 2-aryl-2,2-disubstituted ethyl-1,2,4-triazoles
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
MY115814A (en) 1995-06-16 2003-09-30 Bayer Ip Gmbh Crop protection compositions
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
JP2000344744A (ja) * 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
EP2073741A4 (en) 2006-10-18 2013-07-24 Bnl Biotech Co Ltd ENDODONTIC INSTRUMENT FOR SHUTDOWN OF RADICULAR CHANNEL AND HEATED END SUITABLE FOR THIS INSTRUMENT
JP2010510248A (ja) 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
US8221057B2 (en) 2008-06-25 2012-07-17 General Electric Company Method, system and controller for establishing a wheel space temperature alarm in a turbomachine
NZ591428A (en) 2008-09-03 2013-07-26 Bayer Cropscience Ag Use of bixafen and fluoxastrobin and/or trifloxystrobin for controlling rust in soy bean plants
US8987315B2 (en) * 2009-12-31 2015-03-24 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
SI2563771T1 (sl) * 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
CA2816088A1 (en) * 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2638021B1 (en) * 2010-11-13 2018-09-26 Innocrin Pharmaceuticals, Inc. 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer
AU2011343966B2 (en) * 2010-12-13 2017-03-16 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012177635A1 (en) * 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20140040235A (ko) * 2011-06-19 2014-04-02 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
JP2014523880A (ja) * 2011-06-23 2014-09-18 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素化合物
US9150527B2 (en) * 2011-08-30 2015-10-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
RS57248B1 (sr) * 2011-12-11 2018-07-31 Viamet Pharmaceuticals Nc Inc Jedinjenja inhibitori metaloenzima
IN2014DN06812A (enExample) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
IN2014DN06792A (enExample) * 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
AU2014209107B2 (en) * 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
EP3008051A4 (en) * 2013-06-12 2017-03-01 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2945674A1 (en) * 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
US9663491B2 (en) * 2014-04-15 2017-05-30 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
CA3055292A1 (en) * 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
BR112014017751B1 (pt) 2021-12-07
ES2774267T3 (es) 2020-07-20
WO2013109998A1 (en) 2013-07-25
KR20140116939A (ko) 2014-10-06
JP2015504095A (ja) 2015-02-05
US20150004666A1 (en) 2015-01-01
EP2804858B1 (en) 2019-12-25
EA201491385A1 (ru) 2015-02-27
US20200247779A1 (en) 2020-08-06
BR112014017751A8 (pt) 2021-03-09
EP2804858A4 (en) 2015-07-29
US11247981B2 (en) 2022-02-15
KR102061137B1 (ko) 2019-12-31
DK2804858T3 (da) 2020-03-16
IN2014DN06792A (enExample) 2015-05-22
AU2017232080A1 (en) 2017-10-12
US20190169159A1 (en) 2019-06-06
CA2861339C (en) 2020-08-25
EP2804858A1 (en) 2014-11-26
AU2013209516A1 (en) 2014-08-28
EA026209B1 (ru) 2017-03-31
US10526312B2 (en) 2020-01-07
AU2017232080B2 (en) 2019-02-14
CN104136427A (zh) 2014-11-05
CN104136427B (zh) 2017-03-01
CA2861339A1 (en) 2013-07-25
US10221160B2 (en) 2019-03-05
PL2804858T3 (pl) 2020-06-29

Similar Documents

Publication Publication Date Title
US11247981B2 (en) Metalloenzyme inhibitor compounds
JP5266430B2 (ja) 金属酵素阻害化合物
JP6386035B2 (ja) 金属酵素阻害剤化合物
DK2788343T3 (en) METALLOENZYMIN INHIBITOR COMPOUNDS
CA2942976A1 (en) Antifungal compound process

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170803

R150 Certificate of patent or registration of utility model

Ref document number: 6189865

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250